NASDAQ:BNR Burning Rock Biotech (BNR) Stock Forecast, Price & News $2.23 -0.02 (-0.89%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$2.00▼$2.3350-Day Range$2.25▼$76.5452-Week Range$1.70▼$4.24Volume68,236 shsAverage Volume107,556 shsMarket Capitalization$234.57 millionP/E RatioN/ADividend YieldN/APrice Target$86.61 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Burning Rock Biotech MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside3,836.9% Upside$86.61 Price TargetShort InterestHealthy0.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.69) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsBusiness Services Sector288th out of 330 stocksMedical Laboratories Industry21st out of 22 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $86.61, Burning Rock Biotech has a forecasted upside of 3,836.9% from its current price of $2.20.Amount of Analyst CoverageBurning Rock Biotech has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.71% of the float of Burning Rock Biotech has been sold short.Short Interest Ratio / Days to CoverBurning Rock Biotech has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Burning Rock Biotech has recently decreased by 17.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBurning Rock Biotech does not currently pay a dividend.Dividend GrowthBurning Rock Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNR. Previous Next 1.1 News and Social Media Coverage News SentimentBurning Rock Biotech has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Business Services companies. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Burning Rock Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.10% of the stock of Burning Rock Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Burning Rock Biotech are expected to grow in the coming year, from ($0.69) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Burning Rock Biotech is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Burning Rock Biotech is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBurning Rock Biotech has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Burning Rock Biotech (NASDAQ:BNR) StockBurning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.Read More Receive BNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address BNR Stock News HeadlinesMay 31, 2023 | finance.yahoo.comBurning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Call TranscriptMay 31, 2023 | finance.yahoo.comQ1 2023 Burning Rock Biotech Ltd Earnings CallJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 30, 2023 | finance.yahoo.comBurning Rock Reports First Quarter 2023 Financial ResultsMay 29, 2023 | americanbankingnews.comBurning Rock Biotech (BNR) Set to Announce Earnings on TuesdayMay 16, 2023 | americanbankingnews.comBurning Rock Biotech Limited (NASDAQ:BNR) Short Interest Down 7.1% in AprilMay 13, 2023 | finance.yahoo.comResults: Brenntag SE Exceeded Expectations And The Consensus Has Updated Its EstimatesApril 27, 2023 | finance.yahoo.comBurning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.April 20, 2023 | finance.yahoo.comBurning Rock Publishes 2022 Annual Report on Form 20-FApril 18, 2023 | finance.yahoo.comGreat week for Brenntag SE (ETR:BNR) institutional investors after losing 2.0% over the previous yearApril 17, 2023 | finance.yahoo.comBurning Rock Biotech Limited's (NASDAQ:BNR) Share Price Is Matching Sentiment Around Its RevenuesMarch 28, 2023 | finanznachrichten.deBurning Rock Biotech Limited: Burning Rock Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 28, 2023 | finance.yahoo.comBurning Rock Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 27, 2023 | msn.comEarnings Preview: Burning Rock BiotechMarch 27, 2023 | markets.businessinsider.comBurning Rock Biotech earnings preview: what Wall Street is expectingMarch 26, 2023 | americanbankingnews.comBurning Rock Biotech (BNR) to Release Quarterly Earnings on TuesdayMarch 21, 2023 | americanbankingnews.comAclarion (NASDAQ:ACON) & Burning Rock Biotech (NASDAQ:BNR) Financial ComparisonMarch 19, 2023 | finance.yahoo.comIs Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?March 7, 2023 | finance.yahoo.comBurning Rock Schedules Fourth Quarter and Full Year 2022 Earnings Release on March 28, 2023February 28, 2023 | seekingalpha.comBNR Burning Rock Biotech LimitedFebruary 14, 2023 | finance.yahoo.comEngine Capital Sends Letter to Brenntag’s Supervisory Board of Directors Regarding the Need for a Timely Spin-off of the Specialties BusinessFebruary 14, 2023 | finance.yahoo.comIs Now An Opportune Moment To Examine Brenntag SE (ETR:BNR)?January 31, 2023 | finance.yahoo.comBrenntag's (ETR:BNR) Returns On Capital Are Heading HigherJanuary 17, 2023 | finance.yahoo.comBurning Rock provides an update on 2022 revenue guidanceJanuary 16, 2023 | finance.yahoo.comEven after rising 28% this past week, Burning Rock Biotech (NASDAQ:BNR) shareholders are still down 63% over the past yearJanuary 3, 2023 | markets.businessinsider.comBurning Rock Says FDA Grants Breakthrough Device Designation For OverC Multi-Cancer Blood TestSee More Headlines BNR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNR Company Calendar Last Earnings3/28/2023Today6/07/2023Next Earnings (Estimated)8/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:BNR CUSIPN/A CIK1792267 Webwww.brbiotech.com Phone86-185-0164-1666FaxN/AEmployees1,138Year FoundedN/APrice Target and Rating Average Stock Price Forecast$86.61 High Stock Price Forecast$100.00 Low Stock Price Forecast$76.00 Forecasted Upside/Downside+3,665.7%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-140,820,000.00 Net Margins-157.30% Pretax Margin-152.71% Return on Equity-72.57% Return on Assets-54.29% Debt Debt-to-Equity RatioN/A Current Ratio3.18 Quick Ratio2.86 Sales & Book Value Annual Sales$81.66 million Price / Sales2.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.44Miscellaneous Outstanding Shares105,190,000Free Float73,316,000Market Cap$241.94 million OptionableNot Optionable Beta0.18 Key ExecutivesDr. Shaokun Chuai (Age 44)Chief Scientific Officer & Director Mr. Yusheng Han (Age 44)Founder, Chairman & CEO Mr. Jinxiang Li (Age 38)CFO, Compliance Officer & Director Dr. Zhihong Zhang (Age 47)Chief Technology Officer Mr. Hao Liu (Age 49)Sr. Advisor Key CompetitorsReal BrokerageNASDAQ:REAXLesaka TechnologiesNASDAQ:LSAKOppFiNYSE:OPFIBit DigitalNASDAQ:BTBTOutbrainNASDAQ:OBView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCBought 32,888 shares on 6/1/2023Ownership: 0.062%Geode Capital Management LLCBought 7,311 shares on 5/16/2023Ownership: 0.024%EWA LLCBought 17,253 shares on 5/16/2023Ownership: 0.016%Jane Street Group LLCSold 47,491 shares on 5/16/2023Ownership: 0.010%XTX Topco LtdBought 13,433 shares on 5/15/2023Ownership: 0.013%View All Institutional Transactions BNR Stock - Frequently Asked Questions What is Burning Rock Biotech's stock price forecast for 2023? 0 analysts have issued twelve-month price objectives for Burning Rock Biotech's stock. Their BNR share price forecasts range from $76.00 to $100.00. On average, they expect the company's stock price to reach $86.61 in the next year. This suggests a possible upside of 3,665.7% from the stock's current price. View analysts price targets for BNR or view top-rated stocks among Wall Street analysts. How have BNR shares performed in 2023? Burning Rock Biotech's stock was trading at $59.72 at the beginning of 2023. Since then, BNR shares have decreased by 96.1% and is now trading at $2.30. View the best growth stocks for 2023 here. Are investors shorting Burning Rock Biotech? Burning Rock Biotech saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 608,200 shares, a drop of 17.4% from the April 30th total of 736,000 shares. Based on an average daily trading volume, of 74,400 shares, the short-interest ratio is currently 8.2 days. Approximately 0.7% of the company's shares are short sold. View Burning Rock Biotech's Short Interest. When is Burning Rock Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023. View our BNR earnings forecast. How were Burning Rock Biotech's earnings last quarter? Burning Rock Biotech Limited (NASDAQ:BNR) released its earnings results on Tuesday, March, 28th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $20.62 million for the quarter, compared to analyst estimates of $15.60 million. Burning Rock Biotech had a negative trailing twelve-month return on equity of 72.57% and a negative net margin of 157.30%. What ETFs hold Burning Rock Biotech's stock? ETFs with the largest weight of Burning Rock Biotech (NASDAQ:BNR) stock in their portfolio include Loncar China Biopharma ETF (CHNA), Invesco Golden Dragon China ETF (PGJ), What guidance has Burning Rock Biotech issued on next quarter's earnings? Burning Rock Biotech issued an update on its FY 2023 earnings guidance on Tuesday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.99 million-$97.99 million, compared to the consensus revenue estimate of $95.89 million. What other stocks do shareholders of Burning Rock Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX). When did Burning Rock Biotech IPO? (BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers. What is Burning Rock Biotech's stock symbol? Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR." Who are Burning Rock Biotech's major shareholders? Burning Rock Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.63%), Nikko Asset Management Americas Inc. (0.62%), Barclays PLC (0.58%), Renaissance Technologies LLC (0.35%), Assenagon Asset Management S.A. (0.26%) and Schonfeld Strategic Advisors LLC (0.19%). How do I buy shares of Burning Rock Biotech? Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Burning Rock Biotech's stock price today? One share of BNR stock can currently be purchased for approximately $2.30. How much money does Burning Rock Biotech make? Burning Rock Biotech (NASDAQ:BNR) has a market capitalization of $241.94 million and generates $81.66 million in revenue each year. The company earns $-140,820,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How many employees does Burning Rock Biotech have? The company employs 1,138 workers across the globe. How can I contact Burning Rock Biotech? Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The official website for the company is www.brbiotech.com. The company can be reached via phone at 86-185-0164-1666. This page (NASDAQ:BNR) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Burning Rock Biotech Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.